Skip to content
Pompe Disease News logo
  • About Pompe
    What is Pompe disease?
    Types
    Symptoms
    Causes
    Diagnosis
    Treatment options
    • Lumizyme
    • Nexviazyme
    • Pombiliti + Opfolda
  • News
  • Columns
    Powering Through Pompe — Keara Engle
    Archived columns
    • The Pompe Community Diaries – Anthony Wu
    • On the Road to Pompe — Dwayne Wilson
  • Featured topics
    Living with Pompe
    • Pompe service dog
    • Adaptive clothing
    • Living with Pompe disease
    • ERT and enzyme stabilizers
    • The ERT process
    • Your daily routine with LOPD
    • Adaptive equipment
    • Late-onset Pompe disease
    • Dwayne’s story
    • Expert voice: Safe and effective exercise
    • View all
    Pompe pathways
    • ERT home infusions
    • Therapeutic crossroads
    • Tips for caregivers
    • Maximizing doctor’s appointments
    • Building an LOPD care team
    • Financial planning with Pompe
    • Work and Pompe
    • Occupational therapy
    • Pompe and pain
  • FAQs
  • Advocacy partners
  • What can we help you find today?

May 24, 2022 News by Vanda Pinto, PhD

Avrobio‘s AVR-RD-03 Gene Therapy Effective in Pompe Mouse Model

AVR-RD-03, Avrobio‘s experimental blood stem cell gene therapy for classic infantile-onset Pompe disease, was found to be safe and effective in a mouse model of the disease. The findings, presented as a poster at the 2022 annual meeting of the American Society of Gene & Cell Therapy (ASGCT)…

June 12, 2019 News by Alice Melao

Asthma Medicine Salmeterol Improves Effectiveness of Gene Therapy for Pompe Disease, Mouse Study Suggests

Salmeterol, a vasodilator approved for the treatment of asthma and chronic obstructive pulmonary disease (COPD), has shown potential to improve the effectiveness  of gene therapy for Pompe disease. Studies in mice demonstrated that administering salmeterol as an add-on treatment to gene therapy can significantly reduce the amount…

May 29, 2019 News by Ana Pena, PhD

Gene Therapy Candidate Holds Promise for Correcting Pompe Disease in Muscles and Brain, Mouse Study Suggests

Amicus Therapeutics announced positive preclinical data showing that its investigational gene therapy for Pompe disease is effectively delivered and leads to significant glycogen reduction at key tissues in mice, including the brain and spinal cord.

Recent Posts

  • Genetic test flags Pompe disease in expectant father with no symptoms
  • COL13A1 gene levels may link to Pompe neuromuscular dysfunction
  • Having a nurse at home over the summer has been a big help


Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: [email protected]
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.